FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder
Ye Chen,Zhang Xueying,Cui Jiaqu,Chen Qiyi,Qin Huanlong,Li Ning,Du Yasong,Zhao Xiaoxin,Yang Rong,Lu Jubao,Lv Xiaoqiong,Ma Chunlian,Wang Yu,Chen Shidong,Kuang Guifang,Zhao Dongmei,Fang Shuanfeng,Zhang Xujing,Yang Binrang,Wang Yanxia,Li Ling,Yuan Song,Zhou Xiang,Zhang Beihua,Jiang Lin,Ji Hong,Qin Huanlong,Li Ning,Chen Qiyi,Ye Chen,Zhang Xueying,Cui Jiaqu,Yang Rong,Lu Jubao,Yan Yinmei,Ma Chunlian,Lv Xiaoqiong,Yan Peihua,Huang Linsheng,Zhang Shaoyi,Du Yasong,Zhao Xiaoxin,Wang Yu,Ma Chenhuan,Chen Shidong,Miao Yun,Kuang Guifang,Ling Wenqi,Zhao Dongmei,Li Ning,Fang Shuanfeng,Li Ke,Zhang Xujing,Geng Bojing,Zhang Xin,Yang Binrang,Wang Yanxia,Feng Xueying,Li Lin,Li Huilin,Liu Liyan,Wei Wei,Wu Weijia,Yuan Song,Zhou Xiang,Li Dexin,Zhang Beihua,Jiang Qianru,Jiang Lin
DOI: https://doi.org/10.1136/bmjopen-2021-051613
IF: 3.006
2022-01-01
BMJ Open
Abstract:Introduction Autism spectrum disorder (ASD) is a complicated diffuse developmental disorder that commonly involves gastrointestinal distress and dysbacteriosis. Emerging lines of evidence have shown faecal microbiota transplantation (FMT) to be a potential therapeutic strategy for improving the clinical outcomes of patients with ASD by re-establishing their intestinal microflora. We are undertaking the first-ever multicentre, double-blind, randomised controlled trial of FMT for the treatment of children with both ASD and gastrointestinal symptoms and will assess the feasibility and efficacy outcomes of this strategy. Methods In total, 318 children with both ASD and gastrointestinal symptoms will be enrolled (from 15 hospitals in China) to receive either FMT intervention (n=212) or a placebo (control, n=106). Children aged 3–6 years will take two capsules two times a day, and those older than 6 years will take three capsules two times a day. Each patient will receive four treatment courses, with each 12-day course being repeated every month. Outcomes will be evaluated at baseline, throughout the period of intervention, and at subsequent follow-ups for 2 months. The primary trial objective is to investigate the remodelling effect of FMT on the intestinal microflora in patients with ASD. The secondary objective focuses on the clinical efficacy and safety of FMT, including its improvement of the clinical response and metabonomics. Ethics and dissemination Ethical approval was obtained from the hospital Ethics Committee of each Faecal Transfer for ASD China Multicenter Trial Working Group. The ongoing FMT clinical trial is intended to support the approval of the new technology and its administration. The results of this trial will provide high-quality evidence to inform the future clinical application of this new therapy. Trial registration number ChiCTR2100043906; Pre-results.
medicine, general & internal